Table 1.

Characteristics of treated patients and resultsa

PatientAge at screeningGenderPrior chemotherapy regimens (# lines of therapy: names of agents)Transduced cell dose (× 109)Best overall responseDuration of response (weeks)Peak cell expansion (vector copies/mg DNA)
20041M3: doxorubicin + ifosfamide, ifosfamide, docetaxel + gemcitabine14.355SD.43,181
20132F2: ifosfamide + vincristine + doxorubicin, ifosfamide8.328CR34104,115
20219F2: doxorubicin + ifosfamide, trabectedin6.64PR34110,610
20424F1: doxorubicin, ifosfamide3.79PR1677,401
20519F1: doxorubicin, ifosfamide3.4PR13192,445
20629M2: doxorubicin + ifosfamide, ifosfamide0.451SD.11,265
20727M4: doxorubicin + ifosfamide, Adriamycin + ifosfamide, etoposide + ifosfamide, gemcitabine or docetaxel ± Morab (clinical trial)2.67SD.19,939
20832M3: doxorubicin, ifosfamide, docetaxel + gemcitabine2.23PR72108,233
20932F4: cyclophosphamide, Adriamycin + ifosfamide, ifosfamide, phase I dendritic cell therapy6.45PR2876,185
23018F1: doxorubicin, ifosfamide7.863SD.41,263
26138M4: docetaxel + gemcitabine, pazopanib, MEK inhibitor, ifosfamide0.721SD.17,655
26351M1: doxorubicin2.511SD.119,883
  • aData cutoff March 30, 2017.

  • Abbreviations: F, female; M, male; SD, stable disease.